Has FOXO4-DRI been tested in humans?

No. As of 2026, no registered human clinical trials for FOXO4-DRI have been published. All efficacy and safety data come from rodent models. The compound has not been approved for human use in any jurisdiction.

Why might FOXO4-DRI spare normal cells while targeting senescent ones?

Senescent cells express substantially higher levels of FOXO4 in the nucleus, where it sequesters p53 to prevent apoptosis. Normal proliferating and quiescent cells have low FOXO4–p53 interaction, so competitive displacement of FOXO4 by the peptide is thought to have less effect on them. This selectivity has been demonstrated in mouse models but has not been confirmed in human cell types or tissues.

What is the significance of the D-retro-inverso design?

Using D-amino acids in reversed sequence makes the peptide structurally mimic the natural L-amino acid sequence from the opposite direction. This configuration strongly resists degradation by proteases, which almost exclusively cleave L-amino acid bonds. The result is a compound with greater in vivo stability than an equivalent natural peptide, though human pharmacokinetic data are absent.

Are there risks to clearing senescent cells?

Yes, and they are not trivial. Senescent cells contribute to wound healing, embryonic tissue patterning, and certain immune responses. Excessive or mistimed senolytic activity could impair tissue repair — a particular concern perioperatively or following injury. The long-term consequences of periodic senescent cell depletion in humans, including effects on cancer surveillance and organ homeostasis, are unknown.

How does FOXO4-DRI differ from other senolytics like dasatinib and quercetin?

Dasatinib (a tyrosine kinase inhibitor) and quercetin (a flavonoid) act through broader mechanisms targeting senescent cell survival pathways, and together they have entered early human trials. FOXO4-DRI takes a more targeted approach — directly disrupting a specific protein–protein interaction (FOXO4–p53) — but it has not advanced to human trials. The comparative efficacy and safety of these approaches in humans remains an open research question.

Where can research-grade FOXO4-DRI be sourced, and what quality concerns apply?

FOXO4-DRI is available from research chemical suppliers as an unregulated compound. Quality, purity, sterility, and endotoxin levels are not subject to pharmaceutical regulatory oversight, and vary significantly between suppliers. This introduces meaningful safety uncertainty for any non-laboratory use. It is not a licensed medicine and should only be handled within the context of authorised scientific research.

Longevity

FOXO4-DRI

Also known as: FOXO4-D-Retro-Inverso, FOXO4 DRI, senolytic peptide FOXO4

FOXO4-DRI is a protease-resistant D-retro-inverso peptide designed to selectively induce apoptosis in senescent cells by disrupting the FOXO4–p53 interaction, with efficacy...

Reviewed by the Helica Labs research team · Last updated August 10, 2026

Buy FOXO4-DRI

Overview

FOXO4-DRI (FOXO4-D-Retro-Inverso) is a synthetically engineered peptide senolytic — a compound designed to selectively eliminate senescent cells. Cellular senescence is a state of stable cell cycle arrest that accumulates with age and in response to stress, contributing to chronic inflammation, tissue dysfunction, and age-related pathology. While senescent cells are not simply inert, their persistence in tissue is increasingly understood as a driver of multiple hallmarks of aging. The peptide takes its name from the FOXO4 transcription factor and its structural design: D-amino acids arranged in reverse sequence (retro-inverso) relative to a native FOXO4 segment. This configuration makes the peptide highly resistant to protease degradation compared to conventional L-amino acid peptides, an important pharmacological consideration for in vivo stability. The foundational proof-of-concept study, published in Cell in 2017 by Baar and colleagues, demonstrated that FOXO4-DRI could clear p16(INK4a)-positive senescent cells in mice, reverse markers of frailty in naturally aged animals, improve renal function in a progeroid mouse model, and restore fitness after chemotherapy-induced damage. These findings generated significant interest in the longevity research community and among self-experimenters, though the compound has not progressed to registered human clinical trials as of 2026. Because all published efficacy and safety data are derived from rodent models, the translational relevance to humans remains entirely unknown. FOXO4-DRI is an unregulated research compound, and its use outside controlled laboratory settings carries substantial and incompletely characterised risks.

How it works

In senescent cells, the FOXO4 transcription factor forms a complex with the tumour suppressor p53, retaining p53 within the nucleus and thereby preventing the activation of the intrinsic apoptosis pathway. This pro-survival interaction allows senescent cells to persist despite bearing molecular hallmarks that would ordinarily trigger programmed cell death. FOXO4-DRI is designed to act as a competitive inhibitor of this FOXO4–p53 interaction. By binding p53 with sufficient affinity to displace endogenous FOXO4, the peptide releases p53 from nuclear sequestration, allowing it to translocate to the cytoplasm and mitochondria. There, freed p53 activates the intrinsic (mitochondrial) apoptosis pathway, triggering caspase activation and cell death selectively in senescent cells. The selectivity for senescent over normal cells is proposed to arise from the substantially higher expression and nuclear localisation of FOXO4 in senescent cells. Normal proliferating and quiescent cells exhibit low FOXO4–p53 interaction and are largely spared in mouse model studies. Whether this selectivity holds across diverse human cell types and tissues remains to be established.

Researched effects

Preclinical Selective clearance of p16(INK4a)-positive senescent cells in aged mouse tissue
Preclinical Restoration of physical fitness and coat density in naturally aged mice
Preclinical Improvement of renal function in a progeroid (XpdTTD/TTD) mouse model
Preclinical Reversal of chemotherapy-induced (doxorubicin) frailty in mice
Anecdotal Subjective improvements in energy, skin quality, or recovery reported by some community self-experimenters

Evidence levels: Clinical (human trials) · Preclinical (animal/lab) · Anecdotal (community-reported).

Dosing reference

For research reference only — not a recommendation.

Clinical / studied dosing

No human clinical trials have been published for FOXO4-DRI as of 2026. There is no established clinical dose, dosing interval, or treatment duration for humans. The mouse research protocol used approximately 5 mg/kg administered intraperitoneally three times per week, but direct extrapolation of rodent doses to humans is not scientifically valid without pharmacokinetic and safety data in humans.

Community-reported dosing (anecdotal)

Community protocols are anecdotal and highly variable, with no validated basis. Some self-experimenters attempt to scale from the mouse IP dose (~5 mg/kg x3/week), while others report substantially lower subcutaneous doses. Cycle lengths, intervals, and reconstitution practices vary widely. No community protocol should be interpreted as a safe or effective human dosing regimen. Quality and purity of unregulated research-grade material are additional variables that preclude any reliable dosing guidance.

Half-life: Not characterised in humans. No human pharmacokinetic data exist. In mouse studies, the peptide was administered intraperitoneally and tissue effects were assessed over days to weeks, but plasma half-life was not the study focus. The D-retro-inverso configuration confers substantial resistance to protease degradation compared to native L-amino acid peptides, suggesting a longer circulating half-life than structurally equivalent natural peptides — but the magnitude and clinical relevance of this in humans is unknown.
Routes: Subcutaneous injection (most common in community use), Intraperitoneal injection (used in mouse research), Intravenous injection (reported anecdotally by some community members)

Safety & side effects

FOXO4-DRI has no published human safety data. Key concerns include: (1) Senescent cells are not uniformly harmful — they play essential roles in wound healing, embryonic development, and tissue repair. Indiscriminate or excessive senescent cell clearance could impair these processes, and use around surgery or injury is of particular theoretical concern. (2) The long-term consequences of periodic senescent cell depletion in humans are unknown, including effects on tissue homeostasis, immune surveillance, and tumour suppression. (3) Research-grade peptide sourced from unregulated suppliers carries unknown purity, sterility, and endotoxin risks. (4) The peptide is not approved for human use in any jurisdiction. (5) FOXO4-DRI is not specifically listed on the WADA Prohibited List as of the time of writing, but may fall under the peptide hormones, growth factors, and related substances category depending on regulatory interpretation — athletes should seek specific guidance before use. Administration should only be considered under qualified medical supervision in a properly authorised research context.

Research summary

The primary evidence base for FOXO4-DRI rests on a single landmark mouse study (Baar et al., Cell, 2017), which demonstrated senolytic efficacy across three rodent models: naturally aged mice, a chemotherapy-frailty model, and a progeroid XpdTTD/TTD model. The results were compelling within the constraints of mouse biology and generated substantial downstream interest in the senolytic field. No registered human clinical trials investigating FOXO4-DRI have been published or completed as of 2026. The broader senolytic field has advanced through other compounds — notably dasatinib plus quercetin and navitoclax — which have entered early human trials, but FOXO4-DRI has not followed this translational path in peer-reviewed literature. Key unresolved questions include: human pharmacokinetics and bioavailability by subcutaneous versus intraperitoneal route; the degree of cell-type selectivity in human tissues; the optimal senescent cell burden that warrants therapeutic intervention; the dosing frequency required to maintain benefit without over-depleting beneficial senescent populations; and long-term safety across diverse patient populations. Until these questions are addressed in controlled human studies, FOXO4-DRI remains a preclinical research tool with an uncertain benefit-risk profile in humans.

FAQ

Has FOXO4-DRI been tested in humans?: No. As of 2026, no registered human clinical trials for FOXO4-DRI have been published. All efficacy and safety data come from rodent models. The compound has not been approved for human use in any jurisdiction.
Why might FOXO4-DRI spare normal cells while targeting senescent ones?: Senescent cells express substantially higher levels of FOXO4 in the nucleus, where it sequesters p53 to prevent apoptosis. Normal proliferating and quiescent cells have low FOXO4–p53 interaction, so competitive displacement of FOXO4 by the peptide is thought to have less effect on them. This selectivity has been demonstrated in mouse models but has not been confirmed in human cell types or tissues.
What is the significance of the D-retro-inverso design?: Using D-amino acids in reversed sequence makes the peptide structurally mimic the natural L-amino acid sequence from the opposite direction. This configuration strongly resists degradation by proteases, which almost exclusively cleave L-amino acid bonds. The result is a compound with greater in vivo stability than an equivalent natural peptide, though human pharmacokinetic data are absent.
Are there risks to clearing senescent cells?: Yes, and they are not trivial. Senescent cells contribute to wound healing, embryonic tissue patterning, and certain immune responses. Excessive or mistimed senolytic activity could impair tissue repair — a particular concern perioperatively or following injury. The long-term consequences of periodic senescent cell depletion in humans, including effects on cancer surveillance and organ homeostasis, are unknown.
How does FOXO4-DRI differ from other senolytics like dasatinib and quercetin?: Dasatinib (a tyrosine kinase inhibitor) and quercetin (a flavonoid) act through broader mechanisms targeting senescent cell survival pathways, and together they have entered early human trials. FOXO4-DRI takes a more targeted approach — directly disrupting a specific protein–protein interaction (FOXO4–p53) — but it has not advanced to human trials. The comparative efficacy and safety of these approaches in humans remains an open research question.
Where can research-grade FOXO4-DRI be sourced, and what quality concerns apply?: FOXO4-DRI is available from research chemical suppliers as an unregulated compound. Quality, purity, sterility, and endotoxin levels are not subject to pharmaceutical regulatory oversight, and vary significantly between suppliers. This introduces meaningful safety uncertainty for any non-laboratory use. It is not a licensed medicine and should only be handled within the context of authorised scientific research.

References

All content is for research and educational use only and is not medical advice. Products are sold for laboratory research only and are not for human consumption.